false 0001610853 0001610853 2021-08-17 2021-08-17








Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

August 17, 2021

Date of Report (Date of earliest event reported)


(Exact name of Registrant as Specified in Its Charter)






(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)




642 Newtown Yardley Road, Suite 100

Newtown, PA



(Address of Principal Executive Offices)


(Zip Code)

Registrant’s Telephone Number, Including Area Code: (215) 944-6100

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange on which registered

Common Stock




The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 







Item 5.02                                           Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


As previously disclosed, the employment of Joyce LaViscount, Chief Operating Officer of Helius Medical Technologies, Inc. (the “Company”) ended on July 20, 2021 (the “Separation Date”). In connection with Ms. LaViscount’s notice of intent to resign for “Good Reason” under her employment agreement dated October 19, 2015, as amended (the “Employment Agreement”), following a material change in the nature or scope of Ms. LaViscount’s authority, duties or responsibilities, and the Company’s waiver of its cure opportunity, the Company entered into a Separation and Release Agreement with Ms. LaViscount on August 17, 2021 (the “Separation Agreement”) providing that Ms. LaViscount will receive certain benefits in connection with a termination for “Good Reason”. Under the Separation Agreement, subject to non-revocation of a general release and waiver of claims in favor of the Company, the Company has agreed to pay Ms. LaViscount a total of $442,150 less required deductions and withholdings, paid in approximately equal monthly installments during the twelve-month period following the Separation Date. In addition, the Company has agreed to pay 100% of the cost of premiums for continued health insurance coverage through the earliest of (i) nine months following the Separation Date and (ii) the date Ms. LaViscount becomes eligible for health insurance benefits from a subsequent employer. Ms. LaViscount’s unvested options accelerated as of the Separation Date, as provided in the Employment Agreement, with such options being exercisable through October 18, 2022 (i.e., one year plus 90 days from the Separation Date). Ms. LaViscount also remains subject to the non-compete and non-solicitation provisions in her Employment Agreement during the twelve-month period following the Separation Date. The foregoing summary of the Separation Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Separation Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits






Exhibit No.













Separation and Release Agreement between Helius Medical Technologies, Inc. and Joyce LaViscount, dated August 17, 2021.










Cover Page Interactive Data File (embedded within Inline XBRL document).



























Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.









Dated: August 19, 2021



/s/ Jeffrey S. Mathiesen




Jeffrey S. Mathiesen




Chief Financial Officer and Treasurer



Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Helius Medical Technolog... Charts.
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Helius Medical Technolog... Charts.